eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

Study acronym: eReach2
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 5 more changesShow less
    • Study completion pushed from Jul 1, 2026 to Jul 1, 2027
    • Eligibility criteria expanded, about 8 words
    • Study description revised
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date changed from estimate of Dec 2025 to Dec 24, 2025
    • Study completion date: Jan 2026 to Jul 1, 2026
    v8
  3. Primary completion date: Jul 2025 to Dec 2025v7
  4. 3 versions Re-verified since Oct 5, 2023, no change to tracked fieldsv4-v6
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2022 to Sep 28, 2022
    v3
  6. Start date: Jul 2022 to Sep 2022v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.
Trial Details
NCT Number NCT05427240
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Fox Chase Cancer Center, National Cancer Institute (NCI)
Conditions
(from sponsor)		 Cancer
Related terms Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov